Tumor progression, early diagnosis and prognosis of melanoma

Acta Oncologica

Volumn 38, Issue 5, 1999, Pages 535-548

  Elder, David ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; GROWTH FACTOR; INTEGRIN; TUMOR MARKER;

CANCER GROWTH; CANCER INVASION; CANCER STAGING; DYSPLASTIC NEVUS; EARLY DIAGNOSIS; HUMAN; LENTIGO; MELANOMA; MITOSIS RATE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SUN EXPOSURE;

EID: 0032837961     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699431113     Document Type: Review

References (124)

1. 1. Elder DE, Clark WH Jr, Elenitsas R, et al. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol 1993; 10: 18-35.
2. 2. Elder DE, Van Belle PA, Elenitsas R, Halpern A, Guerry D, IV. Neoplastic progression and prognosis in melanoma. Semin Cutan Med Surg 1996; 10: 336-48.
3. 3. Elder DE, Murphy GF. Malignant tumors (melanomas and related lesions). In: Elder DE, Murphy GF, eds. Melanocytic tumors of the skin. Washington, D.C.: Armed Forces Institute of Pathology, 1991: 103-206.
4. 4. Herlyn M. Structure and function of molecules produced by melanoma cells. In: Herlyn M, ed. Molecular and cellular biology of melanoma. Austin: R.G. Landes Co, 1993: 44-92.
5. 5. Foulds L. Neoplastic development. London and New York: Academic Press, 1969.
6. 6. Rous P, Beard JW. The progression to carcinoma of virus-induced papillomas (Shope). J Exp Med 1935; 62: 523-548e.
7. 7. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23.
8. 8. Clark WH. Tumour progression and the nature of cancer. Br J Cancer 1991; 64: 631-44.
9. 9. Moolgavkar SH. Carcinogenesis models: an overview. Basic Life Sci 1991; 58: 387-396 (discussion).
10. 10. Armitage P, Doll R. The age distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer 1954; 8: 1-12.
11. 11. Cook PJ, Doll R, Fellingham SA. A mathematical model for the age distribution of cancer in man. Int J Cancer 1969; 4: 93-112.
12. 12. Peto R, Roe FJ, Lee PN, et al. Cancer and aging in mice and men. Br J Cancer 1975; 32: 411-26.
13. 13. Den Otter W, Koten JW, Van der Vegt BJ, et al. Oncogenesis by mutations in anti-oncogenes: a view. Anticancer Res 1990; 10: 475-87.
14. 14. Fearon ER, Vogelstein B. A genetic model for colorectal carcinogenesis. Cell 1990; 61: 759-67.
15. 15. Clark WH Jr, Elder DE, Guerry D, IV, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15: 1147-65.
16. 16. Halpern AC, Guerry D, IV, Elder DE, et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993; 100: 346S-9S.
17. 17. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi a central risk factor for cutaneous melanoma. JAMA 1997; 277: 1439-44.
18. 18. Masri GD, Clark WH Jr, Guerry D, IV, et al. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990; 22: 1042-8.
19. 19. Elder DE, Guerry D, IV, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984; 6 Suppl: 55-61.
20. 20. Guerry D, IV, Synnestvedt M, Elder DE, et al. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993; 100: 342S-5S.
21. 21. Clark WH Jr, Elder DE, Guerry D, IV, et al. Model predicting survival in stage 1 melanoma based on tumor progression. JNCI 1989; 81: 1893-904.
22. 22. Felding-Habermann B, Mueller BM, Romerdahl CA, et al. Involvement of integrin αV gene expression in human melanoma tumorigenicity. J Clin Invest 1992; 89: 2018-22.
23. 3, to adhere to lymph node vitronectin. J Clin Invest 1992; 90: 1406-13.
24. 3 integrin associates with a 190-k Da protein that is phosphorylated on tyrosine in response to platelet-derived growth factor, J Biol Chem 1993; 268: 17270-6.
25. 1 integrins during human melanoma cell invasion. Cancer Res 1993; 53: 3411-5.
26. 3, integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992; 89: 1557-61.
27. 27. Lafrenie RM, Podor TJ, Buchanan MR, et al. Up-regulated biosynthesis and expression of endothelial cell vitronectin receptor enhances cancer cell adhesion. Cancer Res 1992; 52: 2202-8.
28. 3, rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994; 91: 8856 60.
29. 29. Hsu M-Y, Shih D-T, Meier F, et al. Adenoviral gene transfer of β3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998 (in press)
30. 30. Gallagher RP, McLean DI, Yang CP, et al. Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children: similarities to melanoma: the Vancouver mole study. Arch Dermatol 1990; 126: 770-6.
31. 31. Holman CD, Armstrong BK, Heenan PJ. Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst 1986; 76: 403-14.
32. 32. Easton DF, Cox GM, Macdonald AM, et al. Genetic susceptibility to naevi a twin study. Br J Cancer 1991; 64: 1164-7.
33. 33. Elder DE, Greene MH, Bondi EE, et al. Acquired melanocytic nevi and melanoma: the dysplastic nevus syndrome. In: Ackerman AB, ed. Pathology of malignant melanoma. New York: Masson, 1981: 185-216.
34. 34. Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a risk faetor for malignant melanoma. J Am Acad Dermatol 1987; 17: 459-68.
35. 35. Klein LJ, Barr RJ. Histologic atypia in clinically benign nevi. A prospective study. J Am Acad Dermatol 1990; 22: 275-82.
36. 36. Clark WH Jr, Reimer RR, Grecne MH, et al. Origin of familial melanomas from heritable melanocytic lesions. Arch Dermatol 1978; 114: 732-8.
37. 37. Reimer RR, Clark WH Jr, Greene MH, et al. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA 1978; 239: 744-6.
38. 38. Elder DE, Goldman LI, Goldman SC, et al. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980; 46: 1787-94.
39. 39. Lynch HT, Frichot BCIII, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15: 352-6.
40. 40. MacKie RM, Freudenberger T, Aitchison TC: Personal risk-factor chart for cutaneous melanoma. Lancet 1989; 2: 487-90.
41. 41. Grob JJ, Andrac L, Romano MH, et al. Dysplastic naevus in non-familial melanoma. A clinicopathological study of 101 cases. Br J Dermatol 1988; 118: 745-52.
42. 42. Kopf AW, Friedman RJ, Rigel DS. Atypical mole syndrome. J Am Acad Dermatol 1990; 22: 117-8.
43. 43. National Institutes of Health: Consensus Development Conference. Diagnosis and treatment of early melanoma. JAMA 1992; 268: 1314-1319.
44. 44. Osterlind A, Tucker MA, Stone BJ, et al. The Danish case-control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer 1988; 42: 319-24.
45. 45. Nordlund JJ, Kirkwood J, Forget BM, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985; 45: 1855-61.
46. 46. Halpern AC, Guerry D, IV, Elder DE, et al. Dysplastic nevi as risk markers of sporadic (non-familial) melanoma: a case-control study. Arch Dermatol 1991; 127: 995-9.
47. 47. Augustsson A, Stierner U, Rosdahl I, et al. Sun exposure, common and dysplastic nevi in melanoma patients and controls. Abstracts, 2nd International Conference on Melanoma 1989; 34 (Abstract).
48. 48. Garbe C, Kruger S, Stadler R, et al. Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 1989; 28: 517-23.
49. 49. Kraemer KH, Greene MH, Tarone R, et al. Dysplastic naevi and cutaneous melanoma risk (letter). Lancet 1983; 2: 1076-7.
50. 50. Elder DE, Green MH, Guerry D, IV, et al. The dysplastic nevus syndrome: our definition. Am J Derrnatopathol 1982; 4: 455-60.
51. 51. Greene MH, Clark WH Jr, Tucker MA, et al. Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med 1985; 312: 91-7.
52. 52. Friedman RJ, Heilman ER, Rigel DS, et al. The dysplastic nevus. Clinical and pathologic features. Dermatol Clin 1985; 3: 239-49.
53. 53. Elder DE, Murphy GF. Benign melanocytic tumors (nevi). In: Elder DE, Murphy GF, eds. Melanocytic tumors of the skin, Washington, D.C.: Armed Forces Institute of Pathology, 1991: 5-81.
54. 54. Ainsworth AM, Folberg R, Reed RJ, et al. Melanocytic nevi, melanocytomas, melanocytic dysplasias, and uncommon forms of melanoma. In: Clark WH Jr, Goldman LI, Mastrangelo MJ, eds. Human malignant melanoma. New York: Grune & Stratton. 1979: 167-208.
55. 55. Clemente C, Cochran A, Elder DE, et al. Histopathologic diagnosis of dysplastic nevi. Concordance among pathologists convened by the WHO melanoma programme. Hum Pathol 1991; 22: 313-9.
56. 56. Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major risk factor for nonfamilial nodular and superficial spreading melanoma. Cancer 1990; 66: 387-95.
57. 57. Meyer LJ, Goldgar DE, Cannon-Albright LA, et al. Number, size, and histopathology of nevi in Utah kindreds. Cytogenet Cell Genet 1992; 59: 167-9.
58. 58. Goldgar DE, Cannon-Albright LA, Meyer LJ, et al. Inheritance of nevus number and size in melanoma DNS kindreds, Cytogenet Cell Genet 1992; 59: 200-2.
59. 59. Green A, Siskind V, Bain C, et al. Sunburn and malignant melanoma. Br J Cancer 1985; 51: 393-7.
60. 60. Augustsson A, Stierner U, Rosdahl I, et al. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol (Stockh) 1991; 71; 518-24.
61. 61. Swerdlow AJ, English J, MacKie RM, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J 1986; 292: 1555-9.
62. 62. Tucker MA, Fraser MC, Goldstein AM, et al. The risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1992.
63. 63. Kraemer KH, Tucker M, Tarone R, et al. Risk of cutaneous melanoma in dysplastic nevus syndrome types A and B (letter). N Engl J Med 1986; 315: 1615-6.
64. 64. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi: markers of increased risk for melanoma. Cancer 1989; 63: 386-9.
65. 65. Dabski K, Milgrom H, Stoll HL Jr. Dysplastic nevus syndrome: association with multiple primary neoplasms. J Surg Oncol 1986; 32: 113-20.
66. 66. Pehamberger H, Honigsmann H, Wolff K. Dysplastic nevus syndrome with multiple primary amelanotic melanomas in oculocutaneous albinism. J Am Acad Dermatol 1984; 11: 731-5.
67. 67. Sigg C, Pelloni F, Schnyder UW. Increased incidence of multiple melanoma in sporadic and familial dysplastic nevus syndrome. Hautarzt 1989; 40: 548-52.
68. 68. Titus Ernstoff L, Duray PH. Ernstoff MS, et al. Dysplastic nevi in association with multiple primary melanoma. Cancer Res 1988; 48: 1016-8.
69. 69. MacKie RM. Multiple melanoma and atypical melanocytic nevi - evidence of an activated and expanded melanocytic system. Br J Dermatol 1982; 107: 621-9.
70. 70. Vasen HFA, Bergman W, Van Haeringen A, et al. The familial dysplastic nevus syndrome. Natural history and the impact of screening on prognosis. A study of nine families in The Netherlands. Eur J Cancer Clin Oncol 1989; 25: 337-41.
71. 71. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA A Cancer J Clin 1985; 35: 130-51.
72. 72. Rigel DS, Friedman RJ. The rationale of the ABCDs of early melanoma. J Am Acad Dermatol 1993; 29: 1060-1.
73. 73. Elder DE, Guerry D, IV, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984; 6: 55-62.
74. 74. Jimbow K, Roth SI, Fitzpatrick TB, et al. Mitotic activity in non-neoplastic melanocytes in vivo as determined by histochemical, autoradiographic, and electron microscopic studies. J Cell Biol 1975; 66: 663-70.
75. 75. Cook MG, Clarke TJ, Humphreys S, et al. The evaluation of diagnostic and prognostic criteria and the terminology of thin cutaneous melanoma by the CRC Melanoma Pathology Panel. Histopathology 1996; 28: 497-312.
76. 76. Clark WH Jr. A classification of malignant melanoma in man correlated with histogenesis and biologic behavior. In: Advances in the biology of the skin. Vol. VIII, New York: Pergamon Press, 1967: 621-647.
77. 77. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 19711; 172: 902-8.
78. 78. Barnhill RL, Fine JA, Roush GC, et al. Predicting five-year outcome lor patients with cutaneous melanoma in a population-based study. Cancer 1996; 78: 427-32.
79. 79. Clark WH Jr, Elder DE, Guerry D, IV. Dysplastic nevi and malignant melanoma. In: Farmer F, Hood AF, eds. The pathology of the skin. Appleton-Century-Crofts, 1990: 682-754.
80. 80. Cochran AJ, Method of assessing prognosis in patients with malignant melanoma. Lancet 1968; 2: 1062-4.
81. 81. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol 1978; 114: 871-3.
82. 82. Clemente CG, Mihm MG, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 130-10.
83. 83. Szymik B, Woosley JT. Further validation of the prognostic model for stage I malignant melanoma based on tumor progression. J Cutan Pathol 1993; 20: 50-3.
84. 84. Herlyn M. Molecular and cellular biology of melanoma. Austin Georgetown: R.G. Landes, 1993.
85. 85. Kath R, Rodeck U, Menssen HD, et al. Tumor progression in the human melanocytic system. Anticancer Res 1989; 9: 865-72.
86. 86. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990; 9: 101-12.
87. 87. Hsu M-Y, Elder DE, Herlyn M. The Wistar (WM) melanoma cell lines. In: Masters JRW, Palsson B, eds. Human cell culture. Vol. 3, Solid Cancers. In press, 1998
88. 88. Balahan G, Herlyn M, Guerry D, IV, et al. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet 1984; 11: 429-39.
89. 89. Parmiter AH, Nowell PC. Cytogenetics of melanocytic tumors. J Invest Dermatol 1993; 100: 254S-8S.
90. 90. Koprowski H, Herlyn M, Balaban G, et al. Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet 1985; 11; 297-302.
91. 91. Fountain JW, Karayiorgou M, Ernstoff MS, et al, Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992; 89: 10557-61.
92. 92. Isshiki K, Seng BA, Elder DE, et al. Chromosome 9 deletion in sporadic and familial melanomas in vivo. Oncogene 1994; 9: 1649-53.
93. 93. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13 -p22. Science 1992; 258: 1148-52.
94. 94. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-40.
95. 95. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15-21.
96. 96. Dracopoli NC, Harnett P, Bale SJ, et al. Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci USA 1989; 86: 4614-8.
97. 97. Millikin D, Meese E, Vogelstein B, et al. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res 1991; 51: 5449-53.
98. 98. Trent JM. Cytogenetics of human malignant melanoma. Cancer Metastasis Rev 1991; 10: 103-13.
99. 99. Parmiter AH, Balaban G, Clark WH Jr, et al. Possible involvement of the chromosome region 10q24 q26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet 1988; 30: 313-7.
100. 100. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993; 53: 2235-8.
101. 101. Albino AP, Nanus DM, Mentle IR, et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989; 4: 1363-74.
102. 102. Meese E, Meltzer PS, Witkowski CM, et al. Molecular mapping of the oncogene myb and rearrangements in malignant melanoma. Genes Chromosomes Caneer 1990; 1: 88-94.
103. 103. Yamanishi DT, Buckmeier JA, Meyskens FL, Jr. Expression of c-jun, jun-B, and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas, J Invest Dermatol 1991; 97: 349-53.
104. 104. Van den Oord JJ, Vandeghinste N, De Ley M, et al. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145: 294-300.
105. 105. Herlyn M, Balaban G, Bennicelli J, et al. Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 1985; 74: 283-9.
106. 106. Rodeck U, Herlyn M. Characteristics of cultured human melanocytes from different stages of tumor progression. Cancer Treat Res 1988; 43: 3-16.
107. 107. Halaban R, Fan B, Ahn J, et al. Growth factors, receptor kinases, and protein lyrosine phosphatases in normal and malignant melanocytes. J Immunother 1992; 12: 154-61.
108. 108. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 1989; 8: 3685-91.
109. 109. Pichon F, Lagarde AE. Autoregulation of McWo metastatic melanoma cell growth: characterization of intracellular (FGF, MGSA) and secreted (PDGF) growth factors. J Cell Physiol 1989; 140: 344-58.
110. 110. Rodeck U, Melber K, Kath R, et al. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol 1991; 97: 20-6.
111. 111. Schadendorf D, Möller A, Algermissen B, et al. 11.-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151: 2667-75.
112. 112. Reisfeld RA. International consensus conference on human melanoma antigens. Melanoma Res 1993; 3: 209-17.
113. 113. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990; 4: 2868-80.
114. 1 subunit with tumor progression. Cancer Res 1990; 50: 6757-64.
115. 115. Klein CE, Steinmayer T, Kaufmann D, et al. Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 1991; 96: 281-4.
116. 116. Danen EHJ, Van Muijen GNP, Van de Wiel-van Kemenade E, et al. Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells. Int J Cancer 1993; 54: 315-21.
117. 117. Klein CE, Dressel D, Steinmayer T, et al. Integrin (2(1 is upreguluted in libroblasts and highly aggressive melanoma cells in three-dimensional collagen lattices and mediates the reorganisation of collagen I fibrils. J Cell Biol 1991; 115: 1427-36.
118. 118. McGregor BC, McGregor JL, Weiss LM, et al. Presence of cytoadhesins (IIb IIIa-like glycoproteins) on human metastatic melanomas but not on benign melanocytes. Am J Clin Pathol 1989; 92; 495-9.
119. 119. Mortarini R, Anichini A. From adhesion to signaling: roles of integrins in the biology of human melanoma. Melanoma Res 1993; 3: 87-97.
120. 120. Elder DE, Van Belle P, Albelda S, et al. Tumor progression-related reactivity of nevi and melanomas with the β3 integrin subunit evaluated by streptavidin immunochemistry in paraffin sections. Lab Invest 1994 (in press)
121. 121. Van Belle PA, Elenitsas R, Satyamoorthy K, et al. Progression-related expression of β3 integrin in melanomas and nevi. Hum Pathol 1999 (in press)
122. 122. Hieken TJ, Farolan M, Ronan SG, et al. Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 1990; 63: 169-73.
123. 123. Cattoretti G, Beeker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki 67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-63.
124. 124. Carey WP Jr, Van Belle P, Elder DE. Tumor progression-related reactivity of nevi and melanomas with the MIB-1 (Ki-67) antigen evaluated by streptavidin immunohistochemistry on paraffin sections. Pigment Cell Res 1994; Suppl 3: 18.